New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more: The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
[google_news title=”” keyword=”glioblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Glioblastoma
- Blackberry Smoke drummer Brit Turner dead at 57on March 4, 2024 at 1:05 pm
American rock band Blackberry Smoke's drummer, Brit Turner, has died at age 57, Fox News Digital confirmed. He had been battling brain cancer since 2022.
- Beloved Blackberry Smoke Drummer Brit Turner Dies at 57 After Battling Glioblastomaon March 4, 2024 at 1:02 pm
Brit Turner, famous drummer with Blackberry Smoke. Turner was a maestro whose drumsticks danced over many people’s hearts. His legacy goes beyond music to include a life lived with tenacity and ...
- Blackberry Smoke Drummer Brit Turner Dies at 57on March 4, 2024 at 12:44 pm
Brit Turner, drummer for the Southern rock band Blackberry Smoke, died at 57, two years after being diagnosed with a cancer of the brain.
- Drummer for legendary southern rock band ‘Blackberry Smoke’ dies at 57on March 4, 2024 at 4:54 am
(WJW) – Brit Turner, drummer and founding member of the Southern rock bank Blackberry Smoke, died at the age of 57. The band posted about his passing on social media.
- Brit Turner of the country rock band Blackberry Smoke dies at 57 after brain tumor diagnosison March 4, 2024 at 4:26 am
Brit Turner, a founding member and drummer for the country rock band Blackberry Smoke, has died at 57 after being diagnosed with glioblastoma in 2022.
- What Is Glioblastoma? Condition Explored Following Blackberry Smoke Drummer Brit Turner's Death At 57on March 4, 2024 at 1:08 am
Brit Turner, co-founder and drummer of Blackberry Smoke, embodied the essence of southern rock with his thunderous rhythms and charismatic stage presence. His contributions to the band's success, ...
- Brit Turner, Drummer for Blackberry Smoke, Dead at 57on March 3, 2024 at 10:17 pm
Brit Turner, the drummer and a founding member of Blackberry Smoke, has died at 57 after a battle with cancer of the brain.
- A tumor in her brain, she wants the option to die peacefully — before it’s too lateon March 2, 2024 at 4:12 pm
Nancy Uden took her place in front of legislators, the first to testify inside the overflowing hearing room near the Minnesota Capitol. A head wrap covered her scalp. It hid 36 electrodes that slow ...
- The White House War On Glioblastomaon March 1, 2024 at 6:00 am
But I do. And no, I’m not talking politics. Joe Biden and I have both lost our loved one to the cruel, relentless and currently incurable brain cancer glioblastoma (GBM). In his case, his beloved son ...
- The Hope And Unkept Promise Of Brain Cancer Clinical Trialson March 1, 2024 at 5:00 am
Clinical trials stand out in the bleak landscape of GBM treatment, where patients typically receive surgery, followed by a regimen of chemotherapy drugs and radiotherapy.
via Bing News